Supernus Pharmaceuticals (SUPN) risk factors, FY2024 10-K

Other

1. 01There are no guarantees that we will be successful in completing these tasks. We will need to continue investing substantial financial and management resources to maintain our commercial sales and marketing infrastructure and recruit and train qualified marketing, sales, and other personnel
2. 02substantial liabilities; and adversely affect our revenues and financial condition. In the event of a withdrawal of any of our products from the market, our revenues would decline significantly, and our business would be seriously harmed and could fail
3. 03If generics or other versions of our products including generics containing one or more of the active pharmaceutical ingredients present in our products are approved and successfully commercialized, our business could be materially harmed
4. 04We are subject to uncertainty relating to payment or managed care reimbursement policies, which, if not favorable for our products or product candidates, could hinder or prevent our commercial success
5. 05We depend on wholesalers, distributors, and specialty pharmacies for the distribution of our products. If we lose any of our significant wholesaler, distributor, or specialty pharmacy accounts, our business could be harmed
6. 06Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 20% of our total product revenue in 2024 and collectively accounted for more than 77% of our total product revenue in 2024
7. 07We may not be able to effectively market and sell our product candidates, if approved, in the U.S
8. 08Final marketing approval of any of our product candidates or approval of additional indications for existing products by the FDA or other regulatory authorities may be delayed, limited, or denied, any of which would adversely affect our ability to generate operating revenues
9. 09approval to commercialize our product candidates. We cannot, therefore, predict the timing of any future revenues from these product candidates
10. 10If we do not obtain marketing exclusivity for our product candidates, our business may suffer
11. 11If the FDA or other applicable regulatory authorities approve generic products that compete with any of our products or product candidates, the sales of our products or the commercial success of our product candidates would be adversely affected
12. 12If our competitors develop or market alternatives for the treatment of our target indications, our commercial opportunities will be reduced or eliminated
13. 13Our products and our product candidates may be subject to restrictions or withdrawal from the market. We may be subject to penalties if we fail to comply with regulatory requirements
14. 14working toward meeting these post-marketing commitments for Qelbree in a timely manner. We also have post-marketing commitment to conduct a new leachable study for ONAPGO, which was approved by the FDA in February 2025
15. 15We also have agreements with leading CMOs to manufacture other commercial products and the API for such products. These CMOs offer a comprehensive range of contract manufacturing services
16. 16Refer to Part I, Item 1—Business—Collaborations and Licensing Agreements, of our Annual Report on Form 10-K for discussion on the different collaborations and licensing arrangements
17. 17Even if our product candidates receive regulatory approval in the U.S., we or our collaborators may not receive approval to commercialize our product candidates outside of the U.S
18. 18Our failure to successfully develop and market our product candidates would impair our ability to grow
19. 19products or technologies to us. The success of this strategy depends partly upon our ability to identify, select, discover and acquire promising pharmaceutical product candidates and approved products, and to manage our spending as expenses related to undertaking clinical trials can be substantial
20. 20We may be unable to acquire product candidates or products
21. 21Our clinical trials for our product candidates may fail to demonstrate acceptable levels of safety, efficacy, or other requirements, which could prevent or significantly delay regulatory approval
22. 22Delays or failures in the completion of clinical development of our product candidates would increase our costs, delay, or limit our ability to generate revenues
23. 23Our products and product candidates may cause undesirable side effects or have other characteristics that limit their commercial potential, delay, or prevent their regulatory approval
24. 24authorities to temporarily or permanently halt product sales, which could have a material adverse effect on our business. As required by the FDA, the labels for our products include precautions and warnings about side effects, and in certain cases, the need for monitoring patients receiving the product
25. 25We may not obtain or maintain the benefits associated with Orphan Drug Designation, including market exclusivity
26. 26Healthcare reform measures could hinder or prevent the commercial success of our products or product candidates
27. 27Additional changes to the HealthCare Reform Law include The American Taxpayer Relief Act of 2012, which reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three years to five years
28. 28Congress may consider other legislation to repeal or replace elements of the HealthCare Reform Law. It is difficult to predict the extent to which any of these changes to the HealthCare Reform Law, or additional changes if made, may impact the Company's business or any financial condition
29. 29Healthcare cost containment legislation and the failure of third-party payors to provide appropriate levels of coverage and reimbursement for the use of products and treatments facilitated by our products could harm our business and prospects
30. 30The assessment of the financial impact of the HealthCare Reform Law on the Company's business is on-going. There can be no assurance that the Company's business will not be materially harmed by future compliance with or changes to the HealthCare Reform Law
31. 31Guidelines and recommendations published by various organizations can reduce the use of our products and product candidates
32. 32We could be involved in additional lawsuits to protect or enforce our patents, which could be expensive, time consuming, distracting, and ultimately unsuccessful
33. 33For more information, refer to Part I, Item 3—Legal Proceedings contained in this Annual Report Form 10-K
34. 34Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation
35. 35Limitations on our patent rights relating to our products and product candidates may limit our ability to prevent third parties from competing with us
36. 36Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our approved products and our product candidates and to use our proprietary technologies without infringing the proprietary rights of third parties
37. 37We face potential litigation and product liability exposures. If successful claims are brought against us, we may incur substantial liabilities
38. 38As we continue to increase the size of our organization, we may experience difficulties in managing growth
39. 39Cybersecurity incidents may adversely impact our financial condition, results of operations, and reputation. Security breaches and other disruptions could compromise our information and expose us to liability which would cause our business and reputation to suffer
40. 40The continued occurrence of high-profile data breaches provides evidence of an external environment which is increasingly hostile to information security and to the secure processing, maintenance, and transmission of information critical to our operations and business strategy
41. 41While integrating acquired businesses and operations and upgrading the Company's information technology systems, we may face an elevated cybersecurity risk
42. 42Our business involves the use of hazardous materials, and we must comply with environmental laws and regulations. This can be expensive and restrict how we do business
43. 43Provisions in our agreement with Shire, or its successor, Takeda Pharmaceutical Company Limited, impose restrictive covenants on us, which could limit our ability to operate effectively in the future
44. 44The Company’s financial condition and results of operations may be materially and adversely affected by health pandemics
45. 45The Company may also experience other unknown impacts from a pandemic that cannot be predicted. We may also experience delays in receiving supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns, stoppages, or disruptions in delivery systems
46. 46There can be no assurance that any of the Company's plans will be effective in mitigating the effects of a pandemic on our business operations and consequently the potential material adverse impact on our anticipated revenue, earnings and liquidity

Risks Related to Our Finances and Capital Requirements

1. 47Our operating results may fluctuate significantly
2. 48We expect that any revenue we generate will fluctuate from quarter to quarter and year to year as a result of the revenue generated from approved products, license agreements, development milestones, and collaboration license agreements
3. 49Our ability to use our net operating loss carryforwards and other tax attributes may be limited or may expire prior to utilization
4. 50Maintaining effective internal control over financial reporting is necessary for us to produce reliable financial statements. Effective internal control over financial reporting and adequate disclosure controls and procedures are designed to prevent fraud
5. 51become subject to litigation or investigations, which could adversely affect our business, operations, financial condition and the trading price of our Common Stock
6. 52We have and may further expand our business through acquisitions of new product lines or businesses, which expose us to various risks, including difficulties in integrating acquisitions. Our recent acquisitions pose certain incremental risks to the Company
7. 53SPN-830, received FDA approval in February 2025, certain milestones related to the FDA approval of the SPN-830 NDA were paid in February 2025, and we expect certain of the remaining regulatory and commercial milestone activities to become due and paid in 2025
8. 54Any impairment in the value of our intangible assets, including goodwill, would negatively affect our operating results and total capitalization
9. 55Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations
10. 56In recent years, we have focused primarily on marketing our current products and developing our product candidates, with the goal of supporting regulatory approval for our product candidates. We have financed our operations through revenue generated from operations and various financing transactions

Risks Related to Securities Markets and Investment in Our Stock

1. 57The issuance of additional shares of our common stock, or instruments convertible into or rights to acquire shares or our common stock, or market sales of our common stock, could affect the market price of our common stock
2. 58The price of our common stock may fluctuate substantially
3. 59Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control, which could negatively impact the market price of our common stock
4. 60To the extent outstanding stock options are exercised and restricted stock units and performance stock units vest there will be dilution to new investors
5. 61Indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition, and results of operations, and impair our ability to satisfy our obligations under the notes
6. 62Our Credit Line is an uncommitted debt facility that may be terminated by the lender at any time
7. 63Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for non-compliance with these requirements
8. 64Our insurance coverage may not be sufficient to cover our legal claims or other losses that we may incur in the future
9. 65We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
10. 66We may enter into significant, complex, and unusual transactions, which may require us to engage outside consultants and financial professionals in order to comply with complex accounting and reporting requirements
11. 67Our operations rely on sophisticated information technology, systems, and infrastructure, a disruption of which could harm our operations
12. 68In addition, unforeseen circumstances may arise, or our strategic imperatives could change, causing us to consume capital significantly faster than we currently anticipate, requiring us to raise additional funds. We have no committed external sources of funds
13. 69Complying with increased financial reporting and securities laws reporting requirements has increased our costs and requires additional management resources. We may fail to meet these obligations
14. 70As a public company, we are subject to Section 404 of SOX relating to internal control over financial reporting. We have and expect to continue to incur significant expense and to devote substantial management effort toward ensuring compliance with Section 404
15. 71We have never paid dividends. Because we do not anticipate paying any cash dividends in the foreseeable future, capital appreciation, if any, of our common stock will be your sole source of gain on an investment in our common stock
16. 72Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price